- Home
- PCSA vs IMCC Comparison
PCSA vs IMCC Comparison
Compare PCSA & IMCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCSA
- IMCC
- Stock Information
- Founded
- PCSA 2011
- IMCC 1980
- Country
- PCSA United States
- IMCC Israel
- Employees
- PCSA N/A
- IMCC N/A
- Industry
- PCSA Biotechnology: Pharmaceutical Preparations
- IMCC Medicinal Chemicals and Botanical Products
- Sector
- PCSA Health Care
- IMCC Health Care
- Exchange
- PCSA Nasdaq
- IMCC Nasdaq
- Market Cap
- PCSA 12.0M
- IMCC 10.4M
- IPO Year
- PCSA N/A
- IMCC N/A
- Fundamental
- Price
- PCSA $0.27
- IMCC $1.00
- Analyst Decision
- PCSA Strong Buy
- IMCC
- Analyst Count
- PCSA 1
- IMCC 0
- Target Price
- PCSA $1.00
- IMCC N/A
- AVG Volume (30 Days)
- PCSA 4.4M
- IMCC 1.3M
- Earning Date
- PCSA 11-06-2025
- IMCC 11-13-2025
- Dividend Yield
- PCSA N/A
- IMCC N/A
- EPS Growth
- PCSA N/A
- IMCC N/A
- EPS
- PCSA N/A
- IMCC N/A
- Revenue
- PCSA N/A
- IMCC $37,606,703.00
- Revenue This Year
- PCSA N/A
- IMCC $47.12
- Revenue Next Year
- PCSA N/A
- IMCC $12.83
- P/E Ratio
- PCSA N/A
- IMCC N/A
- Revenue Growth
- PCSA N/A
- IMCC 1.92
- 52 Week Low
- PCSA $0.15
- IMCC $0.93
- 52 Week High
- PCSA $1.50
- IMCC $7.12
- Technical
- Relative Strength Index (RSI)
- PCSA 43.44
- IMCC 24.51
- Support Level
- PCSA $0.29
- IMCC $1.21
- Resistance Level
- PCSA $0.35
- IMCC $1.54
- Average True Range (ATR)
- PCSA 0.05
- IMCC 0.13
- MACD
- PCSA -0.01
- IMCC -0.01
- Stochastic Oscillator
- PCSA 3.69
- IMCC 10.00
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.